{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:21:51Z","timestamp":1786990911382,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102829"],"award-info":[{"award-number":["82102829"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003231"],"award-info":[{"award-number":["82003231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473255"],"award-info":[{"award-number":["82473255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972846"],"award-info":[{"award-number":["81972846"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023ZD0502200"],"award-info":[{"award-number":["2023ZD0502200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2413900"],"award-info":[{"award-number":["2023YFC2413900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijrobp.2025.12.022","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:01:10Z","timestamp":1766563270000},"page":"1259-1269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Prospective Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy for Patients With 1 to 10 Brain Metastases From Breast Cancer"],"prefix":"10.1016","volume":"124","author":[{"given":"Jin","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.12.022_bib0001","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-021-01424-8","article-title":"Breast cancer brain metastasis: Insight into molecular mechanisms and therapeutic strategies","volume":"125","author":"Wang","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0002","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ijc.33243","article-title":"Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience","volume":"148","author":"Gao","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2019.11.001","article-title":"Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort","volume":"125","author":"Pasquier","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0004","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: Updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0005","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0006","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0007","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0008","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0009","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0011","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.22.00333","article-title":"Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline","volume":"40","author":"Schiff","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0012","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","article-title":"Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases","volume":"125","author":"Kohutek","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0360-3016(03)00568-6","article-title":"Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases","volume":"57","author":"Varlotto","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0014","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3171\/2014.10.JNS141610","article-title":"Adverse radiation effect after stereotactic radiosurgery for brain metastases: Incidence, time course, and risk factors","volume":"123","author":"Sneed","year":"2015","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijrobp.2010.05.033","article-title":"Single-dose versus fractionated stereotactic radiotherapy for brain metastases","volume":"81","author":"Kim","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0016","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2015.10.017","article-title":"Volumetric radiosurgery for 1 to 10 brain metastases: A multicenter, single-arm, phase 2 study","volume":"94","author":"Nichol","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0017","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3 x 9 Gy) Stereotactic radiosurgery for large (>2 cm) brain metastases: A comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0018","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.radonc.2017.03.018","article-title":"Clinical outcomes of patients with limited brain metastases treated with hypofractionated (5\u00d76Gy) conformal radiotherapy","volume":"123","author":"Lockney","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0020","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0021","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S1470-2045(17)30692-7","article-title":"Clinical trial design for local therapies for brain metastases: A guideline by the response assessment in neuro-oncology brain metastases working group","volume":"19","author":"Alexander","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0022","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: Proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2015.1145","article-title":"Japanese Radiation Oncology Study Group I. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: Secondary analysis of the JROSG 99-1 randomized clinical trial","volume":"1","author":"Aoyama","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0024","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3171\/2008.11.JNS08984","article-title":"Stereotactic radiosurgery for metastatic brain tumors: A comprehensive review of complications","volume":"111","author":"Williams","year":"2009","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0025","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijrobp.2009.06.006","article-title":"Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery","volume":"77","author":"Blonigen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0026","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0027","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13014-020-01522-6","article-title":"A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis","volume":"15","author":"Remick","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-012-0868-6","article-title":"Stereotactic radiosurgery and fractionated stereotactic radiotherapy: Comparison of efficacy and toxicity in 260 patients with brain metastases","volume":"109","author":"Fokas","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0029","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0360-3016(03)00014-2","article-title":"Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull","volume":"56","author":"Aoyama","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0030","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1158\/1078-0432.CCR-18-2851","article-title":"Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4","volume":"25","author":"Stumpf","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0031","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-024-04681-8","article-title":"Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: A multicenter retrospective study","volume":"168","author":"Koide","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0032","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41523-024-00711-w","article-title":"Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases","volume":"10","author":"Khatri","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0033","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijrobp.2020.01.051","article-title":"Beyond an Updated Graded Prognostic Assessment (Breast GPA): A prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today","volume":"107","author":"Sperduto","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0034","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13014-023-02293-6","article-title":"Favorable prognosis of breast cancer brain metastases patients with limited intracranial and extracranial metastatic lesions","volume":"18","author":"Shi","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12282-018-0903-3","article-title":"Breast cancer patients with brain metastasis undergoing GKRS","volume":"26","author":"Abu-Khalaf","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0036","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ijrobp.2008.12.031","article-title":"Gamma knife radiosurgery for brain metastases from primary breast cancer","volume":"75","author":"Kased","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0037","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.clon.2020.02.007","article-title":"Treating brain metastases from breast cancer: Outcomes after stereotactic radiosurgery","volume":"32","author":"Wilson","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101213","article-title":"Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry","volume":"8","author":"Riecke","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0039","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1002\/cncr.23088","article-title":"Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis","volume":"110","author":"Altundag","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103675","article-title":"Local hero: A phase II study of local therapy only (stereotactic radiosurgery and \/or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02)","volume":"74","author":"Phillips","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0041","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ijrobp.2019.03.052","article-title":"Initial SRS for patients with 5 to 15 brain metastases: Results of a multi-institutional experience","volume":"104","author":"Hughes","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0042","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/neuonc\/noz006","article-title":"Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis","volume":"21","author":"Kim","year":"2019","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0043","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoncol.2023.5791","article-title":"Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial","volume":"10","author":"Yang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0044","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0045","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with>\/= 2 HER2-directed regimens: Phase III NALA TRIAL","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0046","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(21)00716-6","article-title":"Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): A multicentre, single-arm, two-cohort, phase 2 trial","volume":"23","author":"Yan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.022_bib0047","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625066064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625066064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:31:22Z","timestamp":1773984682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625066064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0360301625066064"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.022","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy for Patients With 1 to 10 Brain Metastases From Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}